Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Videos

Elisabeth Gardiner, CSO of Tevard Biosciences, discusses how transfer RNA is impacting the development of gene therapies for diseases with unmet needs.

Gene Therapy, Rare Diseases, and Transfer RNA

Articles

The company’s new AI agent automates labor-intensive processes involved in trial document management.

Medable Presents AI Agent for Automating Trial Master File Processes at JP Morgan Healthcare Conference

The move brings Amgen first-in-class, small molecule-targeted protein degraders for oncology. 

Amgen Acquires UK Biotech Dark Blue Therapeutics

Laine Mello, director of marketing at Ecolab Bioprocessing, reflects on how the use of digital technologies expanded in the pharma industry in 2025 and how new complex molecules will continue to drive innovation in 2026.

Industry Outlook 2026: Trends Transitioning from 2025 into 2026 

Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals will receive advisory services and funding from UKRI Innovate UK and Canada’s NRC IRAP to develop next-generation genetic medicines.

Genetic Medicines Project Gets Funding from UKRI Innovate UK and Canadian NRC IRAP

Meri Beckwith, Co-CEO of Lindus Health, provides a look at how trends that developed in 2025 will impact the pharmaceutical industry in 2026. 

Quick Execution with Operational Integrity

Feliza Mirasol is the science editor for 

China clears GSK’s Nucala (mepolizumab) for COPD, highlighting growing acceptance in the country for biomarker-driven therapies.


China Clears Mepolizumab for COPD

PharmTech spoke with Campbell Bunce, chief scientific officer, Abzena to find out which trends in 2025 impacted the industry the most.

Industry Outlook 2026: The Impact of Novel Therapies

In this overview, PharmTech takes a look back at significant news in the development and approval of cancer treatment in 2025.

A Year of Advancements in the Treatment of Cancer

How will plans to rework medicines legislation in the European Union impact drug development, innovation, and market exclusivity?

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development